Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24770944 | 0.88 | KDM4E (0.65) | KDM4EALDH1A1FAAHHTTSMN1; SMN2 | |
| SCHEMBL1602490 | 0.88 | KDM4E (0.65) | KDM4ES1PR5ALDH1A1SMN1; SMN2 | |
| SCHEMBL10077200 | 0.85 | S1PR5 (0.47) | KDM4ES1PR5ALDH1A1S1PR1RAB9A | |
| SCHEMBL14421962 | 0.84 | S1PR5 (0.60) | S1PR5S1PR1 | |
| SCHEMBL1281240 | 0.82 | S1PR5 (0.46) | KDM4ES1PR5ALDH1A1S1PR1RAB9A | |
| SCHEMBL10077188 | 0.82 | S1PR5 (0.46) | KDM4ES1PR5ALDH1A1S1PR1RAB9A | |
| SCHEMBL12269427 | 0.81 | ALDH1A1 (0.56) | KDM4ES1PR5ALDH1A1S1PR1FAAH | |
| SCHEMBL18491449 | 0.80 | DRD4 (0.43) | KDM4ES1PR5ALDH1A1HTT | |
| SCHEMBL1688739 | 0.79 | S1PR5 (0.44) | S1PR5S1PR1 | |
| SCHEMBL10077194 | 0.79 | MAOB (0.56) | KDM4EALDH1A1FAAHHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364976-B1 | S1P receptor modulating compounds and use thereof | EPIX PHARM INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2364976-B1 | S1P receptor modulating compounds and use thereof | EPIX PHARM INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20120088749-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088749-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088749-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8080542-B2 | S1P receptor modulating compounds and use thereof | AMGEN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080542-B2 | S1P receptor modulating compounds and use thereof | AMGEN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080542-B2 | S1P receptor modulating compounds and use thereof | AMGEN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2364976-A1 | S1P receptor modulating compounds and use thereof | EPIX Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364976-A1 | S1P receptor modulating compounds and use thereof | EPIX Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2121648-A2 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090082331-A1 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082331-A1 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082331-A1 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009038759-A2 | 1-(4-(BENZYLBENZAMID0) -BENZYL) AZETIDINE-3-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS SLP RECEPTOR MODULATORS FOR THE TREATMENT OF IMMUNE DISORDERS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038759-A2 | 1-(4-(BENZYLBENZAMID0) -BENZYL) AZETIDINE-3-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS SLP RECEPTOR MODULATORS FOR THE TREATMENT OF IMMUNE DISORDERS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2007109334-A2 | SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | KDM4E 1855/4885S1PR5 2/4885ALDH1A1 2501/4885 |
| US-20090082331-A1 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | S1PR1, S1PR4, S1PR2 | KDM4E 1628/4885S1PR5 4/4885ALDH1A1 3108/4885 |
| US-20120088749-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR4, S1PR2 | KDM4E 1229/4885S1PR5 4/4885ALDH1A1 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.